| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
355,150,000 |
| Market
Cap: |
2.20(B) |
| Last
Volume: |
17,273,575 |
Avg
Vol: |
17,226,422 |
| 52
Week Range: |
$6.13 - $10.61 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 400 MIDCAP |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Bausch Health Companies develops, manufactures and markets, primarily in the therapeutic areas of eye-health, gastroenterology and dermatology, a range of: pharmaceuticals, generic and branded generic pharmaceuticals, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Co.'s portfolio of products falls into four operating and reportable segments: Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
6,313 |
13,261 |
14,828 |
| Total Sell Value |
$0 |
$61,867 |
$119,170 |
$133,715 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
4 |
7 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ross Thomas W. Sr. |
Director |
• • – |
2022-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
34,387 |
132,311 |
|
- |
|
| Paulson John |
Director |
• • – |
2022-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
34,387 |
121,016 |
|
- |
|
| Karabelas Argeris N |
Director |
• • – |
2022-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
34,387 |
123,715 |
|
- |
|
| De Schutter Richard U |
Director |
• • – |
2022-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
34,387 |
355,479 |
|
- |
|
| Icahn Brett |
Director |
• • – |
2022-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
34,387 |
47,494 |
|
- |
|
| Barresi John S |
SVP, Controller & CAO |
• • – |
2022-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
16,898 |
16,898 |
|
- |
|
| Mulligan Richard |
Director |
• • – |
2022-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
2,317 |
2,317 |
|
- |
|
| Carson Seana |
EVP, General CounselOfficer |
• – – |
2022-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
68,570 |
|
-24% |
|
| Vadaketh Tom George |
EVP, Chief Financial OfficerOf |
• – – |
2022-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
101,623 |
|
-24% |
|
| Appio Thomas |
Chief Executive Officer |
• • – |
2022-05-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
32,022 |
507,289 |
|
- |
|
| Papa Joseph C |
Director |
– • – |
2022-05-10 |
4 |
D |
$9.40 |
$316,912 |
D/D |
(33,714) |
1,427,568 |
|
- |
|
| Papa Joseph C |
Director |
– • – |
2022-05-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
366,130 |
1,461,282 |
|
- |
|
| Spurr Robert |
President, U.S. Businesses |
• – – |
2022-05-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,235 |
112,741 |
|
- |
|
| Carson Seana |
EVP, General Counsel |
• – – |
2022-05-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,467 |
76,037 |
|
- |
|
| Miller Steven D |
Director |
• • – |
2022-03-31 |
4 |
A |
$22.85 |
$30,619 |
D/D |
1,340 |
63,229 |
|
- |
|
| Robertson Russel C |
Director |
• • – |
2022-03-31 |
4 |
A |
$22.85 |
$38,114 |
D/D |
1,668 |
128,253 |
|
- |
|
| Paulson John |
Director |
• • – |
2022-03-31 |
4 |
A |
$22.85 |
$30,619 |
D/D |
1,340 |
86,629 |
|
- |
|
| Wechsler Amy B |
Director |
• • – |
2022-03-31 |
4 |
A |
$22.85 |
$6,855 |
D/D |
300 |
99,354 |
|
- |
|
| De Schutter Richard U |
Director |
• • – |
2022-03-31 |
4 |
A |
$22.85 |
$34,366 |
D/D |
1,504 |
321,092 |
|
- |
|
| Icahn Brett |
Director |
• • – |
2022-03-31 |
4 |
A |
$22.85 |
$30,619 |
D/D |
1,340 |
13,107 |
|
- |
|
| Spurr Robert |
U.S. President-Pharma Business |
• • – |
2022-03-15 |
4 |
AS |
$22.20 |
$107,581 |
D/D |
(4,846) |
92,101 |
|
-60% |
|
| Ackermann Christina |
EVP AND GENERAL COUNSEL |
• • – |
2022-03-10 |
4 |
D |
$22.56 |
$18,928 |
D/D |
(839) |
162,240 |
|
- |
|
| Gordon Joseph F |
Pres&Co-Head Bausch&Lomb/Intl |
• • – |
2022-03-08 |
4 |
AS |
$21.76 |
$84,625 |
D/D |
(3,889) |
93,139 |
|
-60% |
|
| Appio Thomas |
CEO, Pharma Business |
• • – |
2022-03-03 |
4 |
D |
$23.61 |
$131,366 |
D/D |
(5,564) |
475,267 |
|
- |
|
| Eldessouky Sam |
EVP & Chief Financial Officer |
• • – |
2022-03-03 |
4 |
D |
$23.61 |
$29,324 |
D/D |
(1,242) |
119,455 |
|
- |
|
1058 Records found
|
|
Page 5 of 43 |
|
|
0.13 (2.05%) 
